Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection.
Journal: 1983/November - Journal of Clinical Microbiology
ISSN: 0095-1137
PUBMED: 6619284
Abstract:
We studied a patient who developed acute hepatitis B virus (HBV) infection despite the presence of preexisting antibody to the surface antigen of HBV (anti-HBs). Anti-HBs has been reported to consist primarily of antibody against the common a determinant of HBV. Antibody directed against this major determinant appears to confer protection against HBV, regardless of the subtype. Our patient was shown to have had preexisting anti-HBs of anti-d but not anti-a specificity. She subsequently developed non-A, non-B viral hepatitis followed by an episode of acute hepatitis B after exposure to HBV of the ayw subtype.
Relations:
Content
Citations
(4)
References
(20)
Grants
(1K+)
Diseases
(1)
Chemicals
(2)
Organisms
(1)
Processes
(1)
Similar articles
Articles by the same authors
Discussion board
J Clin Microbiol 18(2): 305-309

Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection.

Abstract

We studied a patient who developed acute hepatitis B virus (HBV) infection despite the presence of preexisting antibody to the surface antigen of HBV (anti-HBs). Anti-HBs has been reported to consist primarily of antibody against the common a determinant of HBV. Antibody directed against this major determinant appears to confer protection against HBV, regardless of the subtype. Our patient was shown to have had preexisting anti-HBs of anti-d but not anti-a specificity. She subsequently developed non-A, non-B viral hepatitis followed by an episode of acute hepatitis B after exposure to HBV of the ayw subtype.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (724K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bancroft WH, Mundon FK, Russell PK. Detection of additional antigenic determinants of hepatitis B antigen. J Immunol. 1972 Oct;109(4):842–848. [PubMed] [Google Scholar]
  • Couroucé-Pauty AM, Soulier JP. Further data on HBs antigen subtypes - geographical distribution. Vox Sang. 1974;27(6):533–549. [PubMed] [Google Scholar]
  • Dodd RY, Holland PV, Ni LY, Smith HM, Greenwalt TJ. Hepatitis B antigen: regional variation in incidence and subtype ratio in the American Red Cross donor population. Am J Epidemiol. 1973 Feb;97(2):111–115. [PubMed] [Google Scholar]
  • Gold JW, Alter HJ, Holland PV, Gerin JL, Purcell RH. Passive hemagglutination assay for antibody to subtypes of hepatitis B antigen. J Immunol. 1974 Mar;112(3):1100–1106. [PubMed] [Google Scholar]
  • Gust ID, Dimitrakakis M, Lucas CR. Changing patterns in the distribution of hepatitis B subtypes. Vox Sang. 1980 Feb;38(2):81–86. [PubMed] [Google Scholar]
  • Heijtink RA, van Hattum J, Schalm SW, Masurel N. Co-occurrence of HBsAg and anti-HBs: two consecutive infections or a sign of advanced chronic liver disease? J Med Virol. 1982;10(2):83–90. [PubMed] [Google Scholar]
  • Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med. 1981;32:1–11. [PubMed] [Google Scholar]
  • Hoofnagle JH, Gerety RJ, Smallwood LA, Barker LF. Subtyping of hepatitis B surface antigen and antibody by radioimmunoassay. Gastroenterology. 1977 Feb;72(2):290–296. [PubMed] [Google Scholar]
  • Koziol DE, Alter HJ, Kirchner JP, Holland PV. The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol. 1976 Dec;117(6):2260–2262. [PubMed] [Google Scholar]
  • Le Bouvier GL. The heterogeneity of Australia antigen. J Infect Dis. 1971 Jun;123(6):671–675. [PubMed] [Google Scholar]
  • Markenson JA, Gerety RJ, Hoofnagle JH, Barker LF. Effects of cyclophosphamide on hepatitis B virus infection and challenge in chimpanzees. J Infect Dis. 1975 Feb;131(2):79–87. [PubMed] [Google Scholar]
  • McAuliffe VJ, Purcell RH, Gerin JL. Type B hepatitis: a review of current prospects for a safe and effective vaccine. Rev Infect Dis. 1980 May-Jun;2(3):470–492. [PubMed] [Google Scholar]
  • Milich DR, Alexander H, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). III. Circumvention of nonresponsiveness in mice bearing HBsAg nonresponder haplotypes. J Immunol. 1983 Mar;130(3):1401–1407. [PubMed] [Google Scholar]
  • Milich DR, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg. J Immunol. 1982 Jul;129(1):320–325. [PubMed] [Google Scholar]
  • Milich DR, Leroux-Roels GG, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). II. Qualitative characteristics of the humoral immune response to the a, d, and y determinants of HBsAg. J Immunol. 1983 Mar;130(3):1395–1400. [PubMed] [Google Scholar]
  • Nielsen JO, Le Bouvier GL. Subtypes of Australia antigen among patients and healthy carriers in Copenhagen. A relation between the subtypes and the degree of liver damage in acute viral hepatitis. N Engl J Med. 1973 Jun 14;288(24):1257–1261. [PubMed] [Google Scholar]
  • Shorey J, Mushahwar IK, Shorey J, Overby LR. Reexamination of hepatitis B virus subtypes and e-antigen expression by radioimmunoassays. J Med Virol. 1982;10(1):1–9. [PubMed] [Google Scholar]
  • Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, DeVera A, Chen GT, Kellner A. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982 Dec 9;307(24):1481–1486. [PubMed] [Google Scholar]
  • Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. [PubMed] [Google Scholar]
  • Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. [PubMed] [Google Scholar]
Abstract
We studied a patient who developed acute hepatitis B virus (HBV) infection despite the presence of preexisting antibody to the surface antigen of HBV (anti-HBs). Anti-HBs has been reported to consist primarily of antibody against the common a determinant of HBV. Antibody directed against this major determinant appears to confer protection against HBV, regardless of the subtype. Our patient was shown to have had preexisting anti-HBs of anti-d but not anti-a specificity. She subsequently developed non-A, non-B viral hepatitis followed by an episode of acute hepatitis B after exposure to HBV of the ayw subtype.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.